BioCentury
ARTICLE | Company News

Biovitrum to spin out R&D subsidiary

January 23, 2009 1:48 AM UTC

Biovitrum (SSE:BVT) plans to spin out its U.K. R&D subsidiary, Cambridge Biotechnology. Cambridge's pipeline of small molecules includes BVT.115959, an adenosine A2A receptor agonist in Phase II testing to treat neuropathic pain; undisclosed Phase I and Phase II programs to treat obesity; a preclinical leptin mimetic program for obesity; as well as one preclinical and four discovery programs for pain and inflammation. Biovitrum said the move reflects the company's previously announced decision to focus its in-house R&D on specialist pharmaceuticals and protein therapeutics (See BioCentury, Sep. 22, 2008). ...